Goal 3: Advance Translational Research

NIH should promote, rather than deter “fast-track” translational research projects

In the current environment, NIH reviewers actually deter, rather than promote, progress on proposed pre-clinical animal research that is most likely to rapidly translate into clinical breakthroughs in the short term. Scientists should be allowed to focus on critical missing information (roadblocks) needed to accelerate a promising treatment to clinical trials. For instance, at the NHLBI there is currently no study section ...more »

Submitted by (@nhlbiforumadministrator)

Voting

9 net votes
18 up votes
9 down votes
Active

Goal 3: Advance Translational Research

Translational Bioinformatics Spanning Multiple Scales of Biologic Complexity to Implement Precision Pulmonary Medicine at the Po

What translational bioinformatics tools could be used in pulmonary medicine to allow multidimensional, multi-scale modeling of clinical and biomolecular data to assist clinical decision-making?

Submitted by (@nhlbiforumadministrator)

Voting

-2 net votes
10 up votes
12 down votes
Active

Goal 3: Advance Translational Research

Incentivizing Translational Research

Support for scientific research depends on making a compelling case that we contribute to the health of Americans and the health of the US economy. This idea is to address the critical challenge of making basic research relevant to the lives of Americans by incentivizing NHBLI researchers to engage meaningfully in translational research.

Submitted by (@tomtherramus)

Voting

16 net votes
25 up votes
9 down votes
Active

Goal 4: Develop Workforce and Resources

Promoting Translational Research training using the R03 mechanism

We in Wisconsin have developed a robust training program for mixed MD and PhD postdocs in a clinical dept and yet their future in research is blocked by few faculty positions, poor funding and over complicated NIH applications. One of the simplest grants is the R03 and we have already had graduates with only a few years postdoc experience succeed in gaining R03 funding. The R03 is a very simple very flexible mechanism. ...more »

Submitted by (@ianbird)

Voting

-1 net votes
10 up votes
11 down votes
Active

Goal 1: Promote Human Health

Transformative Impact of Proteomics

The proteomics field has dramatically progressed over the past 20 years, with advancements and improvements in experimental designs and sample preparation protocols, as well as mass spectrometry equipment, approaches, and analysis. This has resulted in substantial forward progress towards a proteomic pipeline to establish cause and effect mechanisms of cardiovascular disease. There is a need for CV proteomics that resolve ...more »

Submitted by (@mllindsey)

Voting

196 net votes
234 up votes
38 down votes
Active

Goal 3: Advance Translational Research

Infrastructure for human translational research

With the reduction in NCAT support for human translational research, infrastructure support will need to come from the NHLBI. This will increase the cost of most human, mechanistic based RO1 studies by 20-30%. This will exceed the current cap of $500K in many circumstances. The cap will need to be raised or NHLBI and other institutes need to determine how NIH can continue to provide this critical infrastructure.

Submitted by (@gwilliams)

Voting

3 net votes
6 up votes
3 down votes
Active

Goal 2: Reduce Human Disease

Understanding the Genetic & Epigenetic Basis of Congenital Heart Disease?

Over the last thirty years, our fundamental understanding of the genetics and pathogenesis of congenital heart disease has lagged the tremendous advances in the surgical and clinical care of infants with this group of disorders. We need to close this gap with investigation into the genetic basis of congenital heart malformations to develop new models of disease. The goall is translate an improved molecular genetic and ...more »

Submitted by (@jamesr.priestmd)

Voting

22 net votes
37 up votes
15 down votes
Active

Goal 3: Advance Translational Research

pre-SBIR grant mechanism

SBIR STTR programs currently offer funds to support phase 1 and phase 2 development of translation with corporate involvement. Several here have pointed out that there is need for additional NIH support of investigator initiated translation, and I concur. There is indeed need for early stage and pre-IND support. Such a program would support relatively small grants for proof-of-principle studies, pre-clinical work needed ...more »

Submitted by (@wjones7)

Voting

-12 net votes
10 up votes
22 down votes
Active